Spotlight Growth
No Result
View All Result
Monday, July 4, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Catalyst Biosciences (NASDAQ: CBIO) Skyrockets 234% After Selling Assets to Vertex Pharmaceuticals (NASDAQ: VRTX) for $60 Million

by admin
May 23, 2022
in Bio/Med/Pharma
0
Catalyst Biosciences NASDAQ CBIO Asset Sale Vertex Pharmaceuticals VRTX Spotlight Growth

Catalyst Biosciences NASDAQ CBIO Asset Sale Vertex Pharmaceuticals VRTX Spotlight Growth

Catalyst Biosciences, Inc. is engaged as a biopharmaceutical company, which is focused on the research and development of protease therapeutics for unmet needs in disorders of the complement and coagulation systems. Shares of the biopharma company surged 234% during trading on Monday, May 23, 2022. Over the past three months, Catalyst Biosciences has seen average daily volume of 293,780 shares. However, volume of 236.27 million shares or dollar volume of around $300.06 million, exchanged hands during Monday’s trading session.

Shares of Catalyst Biosciences soared after the company announced it had entered into a definitive asset purchase and sale agreement with Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX). Under the terms of the agreement, Catalyst will sell its portfolio of protease medicines, including CB 2782-PEG, for $60 million cash. CB 2782-PEG is a C3-degrader for dry age-related macular degeneration that Catalyst Biosciences acquired from Biogen (NASDQ: BIIB) in March 2022.

The sale comes as Catalyst has been exploring strategic alternatives to maximize value for its shareholders. After the asset sale, the company will just hold its coagulation-related drug candidates and assets, such as marzeptacog alfa (activated, MarzAA), dalcinonacog alfa (DalcA) and CB 2679d-GT.

MarzAA is an SQ-administered, next-gen engineered coagulation Factor VIIa, which is meant to treat episodic bleeding and prophylaxis in patients with rare bleeding disorders. DalcA is a next-gen SQ-administered FIX. The CB 2679d-GT candidate is an AAV-based gene therapy for the construct harboring of the DalcA sequence.

“We have been exploring strategic alternatives to monetize our assets and maximize value for our shareholders. This sale is part of the ongoing strategic process that we announced in February to explore alternatives and create value for shareholders. We have significantly reduced our cash burn and continue to work with our advisors to evaluate additional strategic alternatives for Catalyst,” said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

Tags: acquisitionbiopharmaceuticalsbiotechbiotechnology stocksCatalyst BiosciencesCBIOCBIO stockcommon stockday tradingdow jones todayemerging growthinvestinginvesting newsinvestmentmedicalMergermicrocap stocksNASDAQnewspharmaceuticalspublic companysalessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstockstraderstradingtreatmentVertex PharmaceuticalsVRTXVRTX stockwebull wallstreetbets
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022
Ayurcann CSE AYUR OTCQB AYURF July Product Rollout Canada Spotlight Growth

Ayurcann (CSE: AYUR) (OTCQB: AYURF) Prepares for July New Product Rollout as Distribution Expansion Continues Across Canada

June 27, 2022
NeuroSense Therapeutics NASDAQ NRSN Stage III ALS Biomarker Study Spotlight Growth

NeuroSense Therapeutics (NASDAQ: NRSN) Details PrimeC’s Positive Results from Stage III ALS Biomarker Study

June 27, 2022

Recent News

Emergent Health OTC EMGE LOI Fusion Specialty Pharmacy Spotlight Growth

Emergent Health Corp. (OTC Pink: EMGE) Announces LOI to Acquire Fusion Specialty Pharmacy

June 29, 2022
Decibel Therapeutics NASDAQ DBTX Interim Data Phase 1b DB 020 Spotlight Growth

Decibel Therapeutics (NASDAQ: DBTX) Shares Positive Interim Data of its Ongoing Phase 1b Trial of DB-020

June 28, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested